Affordable label-free Delta Life Science offers photonic integrated circuits that deliver high sensitivity and multiplexing at a lower ownership cost, signaling a strong value proposition for labs constrained by budgets seeking advanced biosensing capabilities.

Research acceleration With a claim of accelerating research by a factor of four, target opportunities include academic labs and pharma R&D teams looking to speed biomarker panel validation, drug development studies, and real-time interaction analysis.

Spinoff pedigree As a spinout of TNO, the company leverages established photonics expertise, which can be leveraged in conversations with research institutions and contract development/analysis organizations seeking credible, technically robust biosensing solutions.

Versatile applications Chips and readout devices applicable to medical research, agriculture, and point-of-care diagnostics open cross-industry selling motions, enabling partnerships with biotech labs, agritech firms, and clinical testing providers.

Cost and access shift By combining affordable sensor technology with label-free, multiplexed capabilities, Delta Life Science can target customers who need comprehensive biomarker studies without the high costs of traditional platforms, including mid-size labs and early-stage pharma groups.